ScholarIQanswers from OpenAlex & ORCID
Maureen F. Zakowski
ResearcherPublications, citations & collaboration network
Maureen F. Zakowski is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Maureen F. Zakowski have?
ScholarIQindexed works
Maureen F. Zakowski has 289 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Maureen F. Zakowski have?
ScholarIQcitation count
Maureen F. Zakowski has 35,455 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Maureen F. Zakowski?
ScholarIQh-index
Maureen F. Zakowski has an h-index of 74 in OpenAlex.
What is the i10-index of Maureen F. Zakowski?
ScholarIQi10-index
Maureen F. Zakowski has an i10-index of 146 in OpenAlex.
What is the OpenAlex record for Maureen F. Zakowski?
ScholarIQopenalex
The OpenAlex for Maureen F. Zakowski is on the source record.
What are the most-cited papers on Maureen F. Zakowski?
ScholarIQmost cited works
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
William Pao, Vincent A. Miller, Maureen F. Zakowski, Jennifer A. Doherty, Katerina Politi, Inderpal S. Sarkaria, Bhuvanesh Singh, Robert T. Heelan, Valerie W. Rusch, Lucinda A. Fulton, Elaine R. Mardis, Doris M. Kupfer, Richard K. Wilson, Mark G. Kris, Harold Varmus
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
William Pao, Vincent A. Miller, Katerina Politi, Gregory J. Riely, Romel Somwar, Maureen F. Zakowski, Mark G. Kris, Harold Varmus
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers
Helena A. Yu, Maria E. Arcila, Natasha Rekhtman, Camelia S. Sima, Maureen F. Zakowski, William Pao, Mark G. Kris, Vincent A. Miller, Marc Ladanyi, Gregory J. Riely
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
William Pao, Theresa Y. Wang, Gregory J. Riely, Vincent A. Miller, Qiulu Pan, Marc Ladanyi, Maureen F. Zakowski, Robert T. Heelan, Mark G. Kris, Harold Varmus
Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study
Kerby Shedden, Jeremy M. G. Taylor, David E. Misek, Andrew C. Chang, Samir Hanash, Rork Kuick, David G. Beer, Steven A. Enkemann, Timothy J. Yeatman, Steven A. Eschrich, Michael E. Gruidl, Anupama Sharma, Tsao Ml, Igor Jurišica, Chang‐Qi Zhu, Daniel Strumpf, Frances A. Shepherd, William L. Gerald, János Szőke, Maureen F. Zakowski, Valerie W. Rusch, Mark G. Kris, Agnès Viale, Noriko Motoi, William D. Travis, Thomas J. Giordano, Keyue Ding, Lesley Seymour, Katsuhiko Naoki, Nathan A. Pennell, Barbara A. Weir, Roel Verhaak, M. Meyerson, Christine Ladd‐Acosta, Todd R. Golub, Barbara Conley, Venkatraman Seshan, Kevin K. Dobbin, Tracy Lively, James W. Jacobson